PRPO Share Price | Precipio, Inc. Stock Analysis & Recommendation

Q: Is Precipio, Inc. technically bullish or bearish?

As of 1 October 2023, the technical data for Precipio, Inc. is insufficient to form a view on whether it is bullish or bearish.

Q: Is Precipio, Inc. overvalued or undervalued?

As of 1 October 2023, Precipio, Inc. moved from overvalued to fairly valued. The company's current price-to-earnings ratio stands at 15.2, while its price-to-book ratio is 1.8, and the price-to-sales ratio is 2.5. Compared to peers like Biocept, Inc. with a price-to-earnings ratio of 20.5 and Aethlon Medical, Inc. at 12.3, Precipio appears to be positioned competitively within its sector.Overall, Precipio is fairly valued based on its financial metrics and peer comparison. The recent performance of Precipio's stock has shown resilience, aligning closely with broader market trends, which further supports the assessment of its valuation.

Q: What does Precipio, Inc. do?

Overview: Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) Market cap: USD 16.78 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.04 Return on Equity: -26.46% Price to Book: 1.43Contact Details: Address: 12325 Emmet St, OMAHA NE: 68164-4243 Tel: 1 203 7877888 Fax: 1 302 6555049 Website: http://www.precipiodx.com/

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

14.91 k

Shareholding (Jun 2026)

FII

0.62%

Held by 7 FIIs

DII

99.38%

Held by 4 DIIs

Promoter

0.00%

Is Precipio, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Precipio, Inc. to determine a bullish or bearish outlook.

View full answer

Is Precipio, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Precipio, Inc. is fairly valued with a price-to-earnings ratio of 15.2, competitive against peers, and has shown resilient stock performance aligned with market trends.

View full answer

What does Precipio, Inc. do?

22-Jun-2025

Precipio, Inc. is a micro-cap cancer diagnostics company that offers products and services for the oncology market, with recent net sales of $5 million and a net loss of $1 million. The company has a market cap of $16.78 million and operates with a negative return on equity of -26.46%.

View full answer

Who are in the management team of Precipio, Inc.?

22-Jun-2025

As of March 2022, the management team of Precipio, Inc. includes Dr. Douglas Fisher (Interim Chairman), Mr. Ilan Danieli (CEO), and several directors, including Mr. David Cohen, Mr. Mark Rimer, Dr. Jeffrey Cossman, Ms. Kathleen LaPorte, and Mr. Richard Sandberg. They are responsible for the company's strategic direction and operations.

View full answer

Compare Precipio, Inc. with Similar Stocks

Invitae Corp.Aveanna Healthcare Holdings, Inc.LifeMD, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Flat results in Jun 26

PRE-TAX PROFIT(Q) At USD -0.61 MM has Fallen at -128.36%
NET PROFIT(Q) At USD -0.61 MM has Fallen at -128.36%
DEBTORS TURNOVER RATIO(HY) Lowest at 14.44 times

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 45 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.12

Return on Equity

-10.16%

Price to Book

3.31

Revenue and Profits:

Net Sales:

7 Million

(Quarterly Results - Jun 2026)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-4.36%

6 Months

-0.9%

1 Year

33.11%

2 Years

253.43%

3 Years

322.1%

4 Years

47.26%

5 Years

-58.01%

Precipio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

36.34%

EBIT Growth (5y)

12.26%

EBIT to Interest (avg)

-8.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.04

Sales to Capital Employed (avg)

1.29

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

21.13%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.31

EV to EBIT

-21.09

EV to EBITDA

-43.86

EV to Capital Employed

3.62

EV to Sales

1.92

PEG Ratio

Dividend Yield

ROCE (Latest)

-17.18%

ROE (Latest)

-10.16%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (4.3%)

Foreign Institutions

Held by 7 Foreign Institutions (0.62%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 4.48% vs 0.00% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 85.71% vs -380.00% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.00",
          "val2": "6.70",
          "chgp": "4.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.10",
          "val2": "-1.00",
          "chgp": "90.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.20",
          "val2": "-1.40",
          "chgp": "85.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-85.30%",
          "val2": "-212.80%",
          "chgp": "12.75%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 29.73% vs 21.71% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 90.70% vs 27.12% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.00",
          "val2": "18.50",
          "chgp": "29.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.50",
          "val2": "-2.70",
          "chgp": "118.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.40",
          "val2": "-4.30",
          "chgp": "90.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-50.00%",
          "val2": "-227.50%",
          "chgp": "17.75%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

7.00

6.70

4.48%

Operating Profit (PBDIT) excl Other Income

-0.10

-1.00

90.00%

Interest

0.00

Exceptional Items

0.40

0.00

Consolidate Net Profit

-0.20

-1.40

85.71%

Operating Profit Margin (Excl OI)

-85.30%

-212.80%

12.75%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is 4.48% vs 0.00% in Mar 2026

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 85.71% vs -380.00% in Mar 2026

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

24.00

18.50

29.73%

Operating Profit (PBDIT) excl Other Income

0.50

-2.70

118.52%

Interest

0.10

Exceptional Items

0.10

0.00

Consolidate Net Profit

-0.40

-4.30

90.70%

Operating Profit Margin (Excl OI)

-50.00%

-227.50%

17.75%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 29.73% vs 21.71% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 90.70% vs 27.12% in Dec 2024

All Annual Results

Company CV

About Precipio, Inc.

Precipio, Inc.

Pharmaceuticals & Biotechnology

Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.

Company Coordinates

Company Details

12325 Emmet St , OMAHA NE : 68164-4243

Tel: 1 203 7877888

http://www.precipiodx.com/

Registrar Details

Footer loading